10-Q: Lakeside Holding Limited Reports Disappointing Q2 Results Amid Revenue Decline and Rising Expenses
Quarterly Report
Lakeside Holding Limited's Q2 results reveal a net loss of $1.9 million, a stark contrast to the previous year's income, driven by decreased revenues and increased operating expenses.
Summary
- Lakeside Holding Limited reported a net loss of $3.3 million for the six months ended December 31, 2024, compared to a net loss of $0.2 million for the same period in 2023.
- Total revenue decreased by 15.3% to $7.7 million, primarily due to a decline in cross-border freight solutions revenue.
- Cross-border airfreight solutions revenue decreased by 23.4% to $4.2 million, while ocean freight solutions revenue decreased by 8.7% to $3.2 million.
- The company started generating revenue from the distribution of pharmaceutical products, amounting to $0.2 million for the six months ended December 31, 2024.
- Cost of revenues decreased slightly by 2.1% to $7.2 million, but gross profit decreased significantly by 71.9% to $0.5 million.
- General and administrative expenses increased by 103.7% to $3.7 million, driven by higher salaries, professional fees, and insurance expenses.
- The company had a loss before income taxes of $3.2 million for the six months ended December 31, 2024, compared to a loss of $0.2 million for the same period in 2023.
- As of December 31, 2024, the company's cash and cash equivalents balance was $1.1 million, with a current ratio of 0.81:1 and negative working capital of $1.1 million.
- The company used approximately $3.3 million of IPO proceeds for marketing and business expansion and $1.9 million for working capital needs.
Sentiment
Score: 3
Explanation: The document presents a negative outlook due to decreased revenues, increased expenses, and a significant net loss. The company also acknowledges material weaknesses in its internal controls, further contributing to the negative sentiment.
Positives
- The company successfully launched a new revenue stream through the distribution of pharmaceutical products, generating $0.2 million in revenue for the six months ended December 31, 2024.
- Revenues from Asia-based customers increased by $1.3 million, or 29.4%, for the six months ended December 31, 2024.
- The company secured $5.35 million in net proceeds from its IPO, strengthening its capital base.
Negatives
- The company experienced a significant decrease in revenue from cross-border freight solutions, particularly in airfreight, due to reduced customer orders and political uncertainties.
- Gross profit decreased substantially due to lower revenues and increased overhead costs.
- General and administrative expenses increased significantly, impacting profitability.
- The company reported a net loss of $3.3 million for the six months ended December 31, 2024, a substantial decline compared to the previous year.
- The company's disclosure controls and procedures were deemed ineffective due to material weaknesses in internal control over financial reporting.
Risks
- The company's ability to expand its customer base and control costs is crucial for future profitability.
- The company faces risks related to maintaining service quality and managing its network of service providers.
- Strategic acquisitions and investments may not be successful and could impact the company's financial condition.
- The company is exposed to risks related to fluctuations in wage rates, fuel prices, and leasing costs.
- The company's reliance on a few major customers and suppliers poses a concentration risk.
- The company's internal control weaknesses could lead to material misstatements in its financial statements.
Future Outlook
The company anticipates lower revenue in the next quarter due to the competitive and uncertain economic environment, and is committed to exploring new customer opportunities while maintaining strong relationships with existing customers.
Management Comments
- Management concludes that it has two reporting segments for the six months ended December 31, 2024: cross-border freight solutions (U.S.) and pharmaceutical distribution (China).
- Management plans to address internal control weaknesses by hiring additional accounting staff, implementing formal procedures and controls, and ameliorating the internal audit.
Industry Context
The company operates in the competitive cross-border supply chain solutions and pharmaceutical distribution industries, facing challenges such as fluctuating fuel prices, changing political regulations, and economic downturns.
Comparison to Industry Standards
- It is difficult to compare Lakeside Holding Limited's results directly to industry standards without more specific information on comparable companies and projects.
- However, the company's decline in revenue and profitability is concerning, as it lags behind industry leaders such as C.H. Robinson and Expeditors International, which have demonstrated more resilience in similar market conditions.
- The company's gross margin of 5.1% for cross-border freight solutions is significantly lower than the industry average, indicating potential inefficiencies in cost management.
- The company's high general and administrative expenses, representing 48.8% of total revenues, also raise concerns about operational efficiency compared to industry benchmarks.
Related Party Transactions
- The company had various transactions with related parties, including Weship Transport Inc., American Bear Logistics (Wuhan) Co., Ltd., American Bear Logistics (Shenzhen) Co., Ltd., and LLL Intermodal Inc., for logistic forwarding services, truck delivery services, and warehouse space subleasing.
- The company provides logistic forwarding services to Weship, ABL Wuhan and ABL Shenzhen and charges Weship, ABL Wuhan and ABL Shenzhen at its regular market rate for the services provided.
- Weship is one of the Company's vendors for truck delivery service.
- The Company subleased portion of its warehouse space to Weship for rental income.
- Intermodal is one of the Company's vendors for truck delivery service.
- ABL Wuhan provides labor force and certain cross-border freight consolidation and forwarding services and is one of our cross-border freight consolidation and forwarding service providers.
Stakeholder Impact
- Shareholders are negatively impacted by the decreased profitability and net loss.
- Employees may face uncertainty due to cost-cutting measures and potential restructuring.
- Customers may experience changes in service quality or pricing due to the company's financial challenges.
- Suppliers and creditors may face increased scrutiny and potential delays in payments.
Next Steps
- The company plans to sublease one of its warehouses in Chicago to mitigate costs and improve its gross profit margin.
- The company intends to fund its future capital expenditures with its existing cash balance, proceeds of loans, and working capital loans from stockholders.
- The company plans to address internal control weaknesses by hiring additional accounting staff, implementing formal procedures and controls, and ameliorating the internal audit.
Key Dates
| Date | Description |
|---|---|
| 2018 | Company founded in Chicago, Illinois. |
| August 28, 2023 | Lakeside Holding Limited established under the laws of the State of Nevada. |
| September 23, 2023 | Reorganization of the legal structure was completed. |
| March 29, 2024 | A 120-for-1 share split was conducted by the Company. |
| June 27, 2024 | Registration statement on Form S-1 declared effective by the SEC. |
| July 1, 2024 | Company closed its initial public offering (IPO). |
| July 10, 2024 | The Company incorporated a wholly-owned subsidiary, Sichuan Hupan Jincheng Enterprise Management Co., Ltd, in China. |
| November 5, 2024 | Sichuan Hupan entered into an equity transfer agreement to acquire 100% of the equity interests in Hupan Pharmaceutical. |
| November 21, 2024 | The transaction to acquire Hupan Pharmaceutical was completed. |
| December 12, 2024 | Wuhan Hupan New Energy Technology limited Co., Ltd (Hupan New Energy) established. |
| December 20, 2024 | Wuhan Ruixinda Technology Limited Co., Ltd (Wuhan Ruixinda) established. |
| December 30, 2024 | Representatives Warrants are exercisable. |
| December 31, 2024 | End of the quarterly period for this report. |
| February 14, 2025 | Date of report signature. |
| June 30, 2029 | Representatives Warrants terminate. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.